Yes, but the answer wasn't particularly comprehensive in a strategy sense. The gist I got was that they needed to focus on getting something to market. Sort of makes sense, that if this R327 is best thing since sliced bread, by having it go gangbusters on successfully treating infected wounds, that would get everyone's focus and so the red carpet would be laid out for any other stuff like UTI such that the pathway would be shortened to quickest possible. With the burns thing, I just wonder whether they aren't as common and usually in healthier cohort of people thus the impetus to use R327 isn't as strong, ie. existing std of care works well enough. I'd like their answer to that but we can ask next year!
RCE Price at posting:
46.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)